Prescrire Int. 2016 May;25(171):130-1.
A cohort study conducted in 2014, using data from France's mandatory health insurance system, has shown a 10-fold increased risk of hospitalisation for enteropathy with olmesartan in comparison with other ARBs (sartans) or ACE inhibitors. The increased incidence of enteropathy with olmesartan compared with other ARBs or ACE inhibitors is well documented. The French drug regulatory agency, ANSM, informed healthcare professionals of these risks in 2014. Yet prescription rates for olmesartan remain high, and new cases of olmesartan-associated enteropathy continue to be reported. Patients would be better served if health professionals stopped using olmesartan and regulators withdrew this drug from the market.
2014年开展的一项队列研究利用法国强制医疗保险系统的数据显示，与其他血管紧张素受体阻滞剂（沙坦类药物）或血管紧张素转换酶抑制剂相比，使用奥美沙坦导致肠道病住院的风险增加了10倍。与其他血管紧张素受体阻滞剂或血管紧张素转换酶抑制剂相比，奥美沙坦导致肠道病发病率增加这一情况有充分记录。法国药品监管机构法国国家药品与健康产品安全局（ANSM）在2014年就已将这些风险告知医疗保健专业人员。然而，奥美沙坦的处方率仍然很高，与奥美沙坦相关的肠道病新病例仍不断有报告。如果医疗保健专业人员停止使用奥美沙坦，监管机构将该药物撤出市场，患者将得到更好的治疗。
